News
-
-
PRESS RELEASE
Jaguar Health Reports First Quarter 2026 Financials
Jaguar Health, Inc. reports significant revenue increase driven by license agreements for Mytesi® and Canalevia®-CA1, focuses on crofelemer development for rare intestinal indications. Upcoming presentations at ESPGHAN Meeting. Info on investor webcast and CEO's virtual presentation -
-
PRESS RELEASE
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
First MVID patient enters active treatment extension phase with liquid crofelemer as adjunctive therapy. Jaguar Health focuses on rare pediatric disease treatment -
-
PRESS RELEASE
Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
Jaguar Health, Inc. receives extension from Nasdaq Hearings Panel for compliance with Listing Rules. Company regained compliance with Publicly Held Shares Requirement -
-
PRESS RELEASE
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Jaguar Health, Inc. discusses developing oral crofelemer for pediatric patients with Intestinal Failure (IF) due to MVID, aiming for Breakthrough Therapy Designation. Initial results show reductions in PS needs -
-
